Diagnostic accuracy of a prototype rapid chlamydia and gonorrhoea recombinase polymerase amplification assay: a multicentre cross-sectional preclinical evaluation.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 14 03 2018
revised: 31 05 2018
accepted: 01 06 2018
pubmed: 16 6 2018
medline: 20 9 2019
entrez: 16 6 2018
Statut: ppublish

Résumé

Rapid and accurate sexually transmitted infection diagnosis can reduce onward transmission and improve treatment efficacy. We evaluated the accuracy of a 15-minute run-time recombinase polymerase amplification-based prototype point-of-care test (TwistDx) for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). Prospective, multicentre study of symptomatic and asymptomatic patients attending three English sexual health clinics. Research samples provided were additional self-collected vulvovaginal swab (SCVS) (female participants) and first-catch urine (FCU) aliquot (female and male participants). Samples were processed blind to the comparator (routine clinic CT/NG nucleic acid amplification test (NAAT)) results. Discrepancies were resolved using Cepheid CT/NG GeneXpert. Both recombinase polymerase amplification and routine clinic NAAT results were available for 392 male and 395 female participants. CT positivity was 8.9% (35/392) (male FCU), 7.3% (29/395) (female FCU) and 7.1% (28/395) (SCVS). Corresponding NG positivity was 3.1% (12/392), 0.8% (3/395) and 0.8% (3/395). Specificity and positive predictive values were 100% for all sample types and both organisms, except male CT FCU (99.7% specificity (95% confidence interval (CI) 98.4-100.0; 356/357), 97.1% positive predictive value (95% CI 84.7-99.9; 33/34)). For CT, sensitivity was ≥94.3% for FCU and SCVS. CT sensitivity for female FCU was higher (100%; 95% CI, 88.1-100; 29/29) than for SCVS (96.4%; 95% CI, 81.7-99.9; 27/28). NG sensitivity and negative predictive values were 100% in FCU (male and female). This prototype test has excellent performance characteristics, comparable to currently used NAATs, and fulfils several World Health Organization ASSURED criteria. Its rapidity without loss of performance suggests that once further developed and commercialized, this test could positively affect clinical practice and public health.

Identifiants

pubmed: 29906594
pii: S1198-743X(18)30462-2
doi: 10.1016/j.cmi.2018.06.003
pmc: PMC6420679
pii:
doi:

Types de publication

Evaluation Study Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

380.e1-380.e7

Subventions

Organisme : Medical Research Council
ID : G0901608
Pays : United Kingdom

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

Stat Med. 1999 Nov 30;18(22):2987-3003
pubmed: 10544302
Int J STD AIDS. 2002 Feb;13(2):91-101
pubmed: 11839163
Sex Transm Infect. 2006 Feb;82(1):49-51
pubmed: 16461603
Sex Transm Infect. 2006 Dec;82 Suppl 5:v1-6
pubmed: 17151023
J Clin Microbiol. 2007 May;45(5):1395-402
pubmed: 17376879
Int J STD AIDS. 2011 Oct;22(10):541-7
pubmed: 21998172
J Clin Microbiol. 2013 Mar;51(3):990-2
pubmed: 23254134
J Clin Microbiol. 2013 Jun;51(6):1666-72
pubmed: 23467600
Korean J Urol. 2013 Feb;54(2):73-7
pubmed: 23550267
Sex Transm Infect. 2014 Mar;90(2):104-11
pubmed: 24273127
BMJ Open. 2014 Jul 23;4(7):e005322
pubmed: 25056977
Sex Transm Infect. 2014 Sep;90(6):474
pubmed: 25118322
Clin Biochem Rev. 2014 Aug;35(3):155-67
pubmed: 25336761
Int J STD AIDS. 2016 Jan;27(1):78-9
pubmed: 25931235
Int J STD AIDS. 2016 Jul;27(8):650-5
pubmed: 26092579
BMJ. 2015 Oct 28;351:h5527
pubmed: 26511519
Int J STD AIDS. 2016 Mar;27(4):251-67
pubmed: 26538553
PLoS One. 2015 Dec 08;10(12):e0143304
pubmed: 26646541
BMC Infect Dis. 2016 Jun 06;16:250
pubmed: 27268218
Infect Dis Obstet Gynecol. 2016;2016:4386127
pubmed: 27313440
Emerg Infect Dis. 2017 Jan;23(1):102-104
pubmed: 27983487
Sex Transm Infect. 2017 Sep;93(6):424-429
pubmed: 28159916
PLoS Med. 2017 Jun 27;14(6):e1002330
pubmed: 28654670

Auteurs

E M Harding-Esch (EM)

Applied Diagnostic Research & Evaluation Unit (ADREU), Institute for Infection & Immunity, St George's University of London, London, UK; HIV/STI Department, National Infection Service, Public Health England, London, UK.

S S Fuller (SS)

Applied Diagnostic Research & Evaluation Unit (ADREU), Institute for Infection & Immunity, St George's University of London, London, UK; HIV/STI Department, National Infection Service, Public Health England, London, UK.

S-L C Chow (SC)

Applied Diagnostic Research & Evaluation Unit (ADREU), Institute for Infection & Immunity, St George's University of London, London, UK.

A V Nori (AV)

Applied Diagnostic Research & Evaluation Unit (ADREU), Institute for Infection & Immunity, St George's University of London, London, UK; HIV/STI Department, National Infection Service, Public Health England, London, UK; St George's University Hospitals NHS Foundation Trust, London, UK.

M A Harrison (MA)

Applied Diagnostic Research & Evaluation Unit (ADREU), Institute for Infection & Immunity, St George's University of London, London, UK.

M Parker (M)

TwistDx Limited, Cambridge, UK.

O Piepenburg (O)

TwistDx Limited, Cambridge, UK.

M S Forrest (MS)

TwistDx Limited, Cambridge, UK.

D G Brooks (DG)

TwistDx Limited, Cambridge, UK.

R Patel (R)

Department of Sexual Health, University of Southampton, Southampton, UK.

P E Hay (PE)

St George's University Hospitals NHS Foundation Trust, London, UK.

N Fearnley (N)

Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.

M J Pond (MJ)

Applied Diagnostic Research & Evaluation Unit (ADREU), Institute for Infection & Immunity, St George's University of London, London, UK.

J K Dunbar (JK)

HIV/STI Department, National Infection Service, Public Health England, London, UK.

P D Butcher (PD)

Applied Diagnostic Research & Evaluation Unit (ADREU), Institute for Infection & Immunity, St George's University of London, London, UK.

T Planche (T)

Applied Diagnostic Research & Evaluation Unit (ADREU), Institute for Infection & Immunity, St George's University of London, London, UK; St George's University Hospitals NHS Foundation Trust, London, UK.

C M Lowndes (CM)

Applied Diagnostic Research & Evaluation Unit (ADREU), Institute for Infection & Immunity, St George's University of London, London, UK; HIV/STI Department, National Infection Service, Public Health England, London, UK.

S T Sadiq (ST)

Applied Diagnostic Research & Evaluation Unit (ADREU), Institute for Infection & Immunity, St George's University of London, London, UK; HIV/STI Department, National Infection Service, Public Health England, London, UK; St George's University Hospitals NHS Foundation Trust, London, UK. Electronic address: ssadiq@sgul.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH